Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Seltzer

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Therapeutic Innovation & Regulatory Science|September 19, 2018
An Estimate of the Benefit-Cost Impact of the FDA Guidance on Data Monitoring CommitteesJonathan Seltzer
Therapeutic Innovation & Regulatory Science|May 2, 2018
Safety Reporting: It Can Enter the 21st Century-If We Let ItJonathan Seltzer, Amit Bhattacharyya
American Heart Journal|June 18, 2026
Brief Communication: Biomarkers as endpoints in cardiovascular clinical trials -Report from the Cardiovascular Sciences Research ConsortiumKatarina Zeder, Jonathan Seltzer, Christopher DeFilippi
Future Cardiology|October 7, 2009
Future directions in antiarrhythmic drug therapy for atrial fibrillationSimone Musco, Jonathan Seltzer, Peter R Kowey
American Heart Journal|June 27, 2026
Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research ConsortiumJessica N Holtzman, Gregory M Marcus, Jonathan Seltzer
Journal of Cardiovascular Electrophysiology|June 8, 2007
Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillationJames A Lally, Eric M Gnall, Jonathan Seltzer, et al.
JAMA Internal Medicine|September 30, 2014
Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelinesMuhammad Rizwan Sardar, Marwan Badri, Catherine T Prince, et al.
Biometrical Journal. Biometrische Zeitschrift|December 28, 2018
The changing landscape of data monitoring committees-Perspectives from regulators, members, and sponsorsAmit Bhattacharyya, Paul Gallo, Adam Crisp, et al.
American Heart Journal|June 15, 2016
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tankJames A Reiffel, Jeffrey I Weitz, Paul Reilly, et al.
American Heart Journal|September 23, 2021
The COVID-19 pandemic and cardiovascular issues in clinical trials: Practical and regulatory issues in remote monitoring of cardiac safetyJonathan Seltzer, Fortunato Senatore, Ken Faulkner, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Therapeutic Innovation & Regulatory Science|September 19, 2018
An Estimate of the Benefit-Cost Impact of the FDA Guidance on Data Monitoring CommitteesJonathan Seltzer
Therapeutic Innovation & Regulatory Science|May 2, 2018
Safety Reporting: It Can Enter the 21st Century-If We Let ItJonathan Seltzer, Amit Bhattacharyya
American Heart Journal|June 18, 2026
Brief Communication: Biomarkers as endpoints in cardiovascular clinical trials -Report from the Cardiovascular Sciences Research ConsortiumKatarina Zeder, Jonathan Seltzer, Christopher DeFilippi
Future Cardiology|October 7, 2009
Future directions in antiarrhythmic drug therapy for atrial fibrillationSimone Musco, Jonathan Seltzer, Peter R Kowey
American Heart Journal|June 27, 2026
Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research ConsortiumJessica N Holtzman, Gregory M Marcus, Jonathan Seltzer
Journal of Cardiovascular Electrophysiology|June 8, 2007
Non-antiarrhythmic drugs in atrial fibrillation: a review of non-antiarrhythmic agents in prevention of atrial fibrillationJames A Lally, Eric M Gnall, Jonathan Seltzer, et al.
JAMA Internal Medicine|September 30, 2014
Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelinesMuhammad Rizwan Sardar, Marwan Badri, Catherine T Prince, et al.
Biometrical Journal. Biometrische Zeitschrift|December 28, 2018
The changing landscape of data monitoring committees-Perspectives from regulators, members, and sponsorsAmit Bhattacharyya, Paul Gallo, Adam Crisp, et al.
American Heart Journal|June 15, 2016
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tankJames A Reiffel, Jeffrey I Weitz, Paul Reilly, et al.
American Heart Journal|September 23, 2021
The COVID-19 pandemic and cardiovascular issues in clinical trials: Practical and regulatory issues in remote monitoring of cardiac safetyJonathan Seltzer, Fortunato Senatore, Ken Faulkner, et al.
Pageof 3